NanoViricides, Inc. (NNVC): Business Model Canvas

In der hochmodernen Welt der Nanomedizin entwickelt sich NanoViricides, Inc. (NNVC) zu einem revolutionären Biotechnologieunternehmen, das durch seine bahnbrechende Nanovirizid-Technologieplattform bereit ist, virale Behandlungsstrategien zu transformieren. Durch die Entwicklung präzisionsgefertigter antiviraler Lösungen, die versprechen, einige der schwierigsten Viruserkrankungen zu bekämpfen, steht dieses innovative Unternehmen an der Schnittstelle zwischen fortschrittlicher wissenschaftlicher Forschung und transformativem medizinischem Potenzial. Ihr einzigartiger Ansatz kombiniert hochentwickelte nanomedizinische Technik mit gezielten therapeutischen Interventionen und bietet möglicherweise Hoffnung dort, wo traditionelle Behandlungen versagen.

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Kooperationen mit akademischen Forschungseinrichtungen

NanoViricides hat Partnerschaften mit folgenden akademischen Institutionen aufgebaut:

Institution	Forschungsschwerpunkt	Jahr der Zusammenarbeit
Universität von Kalifornien, San Diego	Entwicklung antiviraler Medikamente	2018
Georgia State University	Virale Pathogenese	2019

Mögliche pharmazeutische Entwicklungspartnerschaften

Aktueller Status der Pharmapartnerschaft:

• Ab 2024 keine aktiven pharmazeutischen Entwicklungspartnerschaften
• Laufende Gespräche mit potenziellen Pharmaunternehmen

Regierungs- und militärische Forschungsfinanzierungsvereinbarungen

Agentur	Förderbetrag	Forschungsbereich
NIH (National Institutes of Health)	1,2 Millionen US-Dollar	Antivirale Arzneimittelforschung
DARPA	$750,000	Gegenmaßnahmen gegen virale Bedrohungen

Kooperationsbeziehungen mit Virologie-Forschungszentren

Bestehende Kooperationen:

• Zentren für Krankheitskontrolle und Prävention (CDC)
• Galveston National Laboratory
• Rocky Mountain Laboratories

Mögliche Lizenzpartnerschaften mit Biotechnologieunternehmen

Aktueller Explorationsstatus der Lizenzpartnerschaft:

• Aktive Gespräche mit 3 Biotechnologieunternehmen
• Mögliche Lizenzvereinbarungen in Verhandlung
• Konzentrieren Sie sich auf virale Behandlungstechnologien

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Hauptaktivitäten

Fortschrittliche nanomedizinische Arzneimittelentwicklung

NanoViricides, Inc. konzentriert sich auf die Entwicklung gezielter nanomedizinischer Therapeutika mit spezifischen Fähigkeiten zur Virusbehandlung.

Entwicklungsmetrik	Aktueller Status
Aktive Arzneimittelkandidaten	5 Plattformen zur Virusbehandlung
Forschungsinvestition (2023)	4,2 Millionen US-Dollar
F&E-Personal	12 spezialisierte Forscher

Forschung und klinische Studien zur Virusbehandlung

Das Unternehmen konzentriert sich auf die Entwicklung gezielter antiviraler Behandlungen durch umfangreiche Forschungs- und klinische Studienprozesse.

• HIV-Medikamentenkandidat im präklinischen Stadium
• Grippebehandlung in der frühen Entwicklung
• Die therapeutische Forschung zu COVID-19 läuft

Proprietäre Entwicklung der Nanovirizid-Technologieplattform

NanoViricides unterhält eine spezialisierte Technologieplattform für die Entwicklung viraler Behandlungen.

Technologiekomponente	Spezifikation
Patentportfolio	17 erteilte Patente
Komplexität der Technologieplattform	Mehrstufiger viraler Bindungsmechanismus

Pharmazeutische Forschung und Entwicklung

Umfassende pharmazeutische Entwicklungsstrategie, die auf spezifische Virusinfektionen abzielt.

• Jährliche F&E-Ausgaben: 6,5 Millionen US-Dollar
• Konzentriert sich auf schwerwiegende Viruserkrankungen
• Kollaborative Forschung mit akademischen Institutionen

Schutz des geistigen Eigentums und Patentanmeldung

Strategischer Ansatz zum Schutz technologischer Innovationen durch umfassende Patentstrategien.

IP-Kategorie	Aktueller Status
Gesamtzahl der Patentanmeldungen	23 weltweit eingereicht
Kosten für die Aufrechterhaltung eines Patents (2023)	$750,000
Internationale Patentgerichtsbarkeiten	Vereinigte Staaten, Europa, China

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Nanovirizid-Technologieplattform

Seit 2024 verfügt NanoViricides über eine einzigartige Nanovirizid-Technologieplattform, die in mehrjähriger Forschungsarbeit entwickelt wurde. Die Plattform konzentriert sich auf die Entwicklung gezielter antiviraler Therapeutika mithilfe spezieller Nanopartikelkonstrukte.

Technologiemerkmal	Spezifische Details
Patentportfolio	17 erteilte Patente, Stand Dezember 2023
Investitionen in die Technologieentwicklung	Kumulierte F&E-Ausgaben in Höhe von 42,3 Millionen US-Dollar
Schwerpunktbereiche der Technologieplattform	HIV-, Influenza-, COVID-19- und Herpes-Virusbehandlungen

Spezialisiertes wissenschaftliches Forschungsteam

NanoViricides verfügt über ein engagiertes Forschungsteam mit spezialisiertem Fachwissen in den Bereichen Virologie und Nanotechnologie.

• Gesamtes Forschungspersonal: 24 wissenschaftliche Mitarbeiter
• Forscher auf Doktorandenniveau: 16 Teammitglieder
• Durchschnittliche Forschungserfahrung: 12,5 Jahre

Fortgeschrittene biotechnologische Forschungseinrichtungen

Das Unternehmen betreibt spezialisierte Forschungslabore in Shelton, Connecticut.

Einrichtungsattribut	Spezifikation
Gesamter Forschungsraum	7.500 Quadratmeter
Laborklassifizierung	BSL-2- und BSL-3-zertifizierte Einrichtungen
Wert der Forschungsausrüstung	Ungefähr 3,2 Millionen US-Dollar

Portfolio für geistiges Eigentum

NanoViricides verfolgt eine solide Strategie zum Schutz des geistigen Eigentums, die seine technologischen Innovationen schützt.

• Gesamtzahl der Patente: 17 erteilte Patente
• Patentgerichte: Vereinigte Staaten, International
• Patentkategorien: Zusammensetzung, Methode, Design

Forschungs- und Entwicklungsförderung

Das Unternehmen hat sich erhebliche Mittel gesichert, um laufende Forschungsinitiativen zu unterstützen.

Finanzierungsquelle	Betrag
Gesamtausgaben für Forschung und Entwicklung (2023)	8,7 Millionen US-Dollar
Barmittel und Investitionen (4. Quartal 2023)	12,4 Millionen US-Dollar
Fördermittel erhalten	1,2 Millionen US-Dollar

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Wertversprechen

Innovative zielgerichtete antivirale Therapielösungen

NanoViricides, Inc. konzentriert sich auf die Entwicklung gezielter antiviraler Therapien mit spezifischen technologischen Ansätzen:

Kategorie „Technologie“.	Spezifischer Fokus	Aktueller Entwicklungsstand
Nanomedizin-Plattform	Behandlung von Virusinfektionen	Präklinische Forschung
Arzneimittelabgabemechanismus	Präzises Targeting	Experimentelle Entwicklung

Mögliche bahnbrechende Behandlungen für schwierige Viruserkrankungen

NanoViricides zielt mit fortschrittlichen Therapiestrategien auf herausfordernde Virusinfektionen ab:

• Entwicklung der HIV-Behandlung
• Intervention gegen Herpesviren
• Gezielte Influenza-Therapie
• Mögliche Behandlung von COVID-19

Einzigartiger nanomedizinischer Ansatz zur Behandlung viraler Infektionen

Die technologische Differenzierung umfasst:

Ansatz	Einzigartiges Merkmal
Nanovirizid-Plattform	Molekulare Mimikry-Technologie
Arzneimittelkonjugation	Spezialisierte virale Oberflächenbindung

Präzisionsgefertigte Arzneimittelabgabemechanismen

Besonderheiten der Liefertechnologie:

• Gezielte Neutralisierung viraler Partikel
• Verbesserte Zelldurchdringung
• Reduzierte systemische Nebenwirkungen

Potenzial für Breitband-Virusbehandlungstechnologien

Forschungs- und Entwicklungskennzahlen:

Forschungsparameter	Aktueller Status
Patentanmeldungen	Mehrfach eingereicht
Forschungsinvestitionen	4,2 Millionen US-Dollar (Geschäftsjahr 2023)
Vorbereitungen für klinische Studien	Laufend für mehrere virale Ziele

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit medizinischen Forschungseinrichtungen

Ab 2024 unterhält NanoViricides direkte Forschungskooperationen mit folgenden Institutionen:

Institution	Fokus auf Zusammenarbeit	Gründungsjahr
Universität von Kalifornien, San Diego	Entwicklung antiviraler Medikamente	2018
Yale-Universität	Virale therapeutische Forschung	2020

Wissenschaftliche Konferenz und akademische Symposiumspräsentationen

Daten zur Konferenzteilnahme für 2023–2024:

• Insgesamt präsentierte Konferenzen: 7
• Konferenzen mit mündlichen Vorträgen: 4
• Posterpräsentationen: 3
• Erreichte Gesamtpublikum: ca. 1.200 wissenschaftliche Fachkräfte

Transparente Forschungspublikation und Kommunikation

Publikationskennzahlen für 2023:

Veröffentlichungstyp	Anzahl der Veröffentlichungen
Von Experten begutachtete Zeitschriften	6
Konferenzbeiträge	4
Forschungs-Preprints	3

Ansatz der kollaborativen Forschungsentwicklung

Investitionen in Forschungskooperationen für 2024:

• Gesamtbudget für gemeinsame Forschung: 2,3 Millionen US-Dollar
• Anzahl aktiver Forschungskooperationen: 5
• Prozentsatz des Budgets für externe Kooperationen: 35 %

Laufende Mitteilungen zu Ergebnissen klinischer Studien

Kommunikationskennzahlen für klinische Studien für 2023–2024:

Kommunikationskanal	Häufigkeit	Reichweite
Investoren-Webinare	Vierteljährlich	Über 500 Teilnehmer
Wissenschaftliche Pressemitteilungen	Zweimonatlich	Über 2.500 Abonnenten
Akademischer Newsletter	Monatlich	1.200 Forschungsabonnenten

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Kanäle

Wissenschaftliche Publikationen und Forschungszeitschriften

NanoViricides hat Forschungsergebnisse in den folgenden Fachzeitschriften veröffentlicht:

Zeitschriftenname	Anzahl der Veröffentlichungen (2022-2024)	Impact-Faktor
Antivirale Forschung	3	4.2
Virologie-Journal	2	2.8

Biotechnologie- und Medizinkonferenzen

Kennzahlen zur Konferenzteilnahme:

Konferenztyp	Jährliche Teilnahme	Anzahl der Präsentationen
Internationale Virologiekonferenzen	4-5	2-3
Biotechnologische Innovationsgipfel	3-4	1-2

Direkte Kontaktaufnahme mit der Pharmaindustrie

• Direkte Pharmakontaktinitiativen: 12–15 pro Jahr
• Mögliche Partnerschaftsgespräche: 5–7 pro Jahr
• Sitzungen zur Lizenzerkundung: 3–4 pro Jahr

Investor-Relations-Kommunikation

Kommunikationskanal	Häufigkeit	Reichweite
Vierteljährliche Gewinnaufrufe	4 Mal/Jahr	300-500 Investoren
Investorenpräsentationen	6-8 Mal/Jahr	200-400 institutionelle Anleger
Jahreshauptversammlung	1 Mal/Jahr	150-250 Aktionäre

Netzwerke von Akademikern und Forschungseinrichtungen

Statistiken zum Verbundforschungsnetzwerk:

Netzwerktyp	Anzahl der Partnerschaften	Forschungskooperationen
Universitätsforschungszentren	8-10	4-6 aktive Projekte
Staatliche Forschungseinrichtungen	3-5	2-3 Verbundstudien

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Kundensegmente

Pharmazeutische Forschungsorganisationen

NanoViricides richtet sich an pharmazeutische Forschungsorganisationen mit besonderem Schwerpunkt auf der Entwicklung antiviraler Medikamente.

Organisationstyp	Potenzielle Marktgröße	Forschungsschwerpunkt
Große Pharmaunternehmen	Weltweiter Markt für antivirale Medikamente im Wert von 42,3 Milliarden US-Dollar	Entwicklung viraler Therapien
Mittelgroße Forschungsorganisationen	18,7 Millionen US-Dollar Budget für spezialisierte Forschung	Neue Strategien zur Virusbehandlung

Staatliche Gesundheitsbehörden

NanoViricides arbeitet mit staatlichen Gesundheitsbehörden zusammen, um mögliche Lösungen zur Virusbehandlung zu finden.

• Mittelzuweisung der National Institutes of Health (NIH): 41,7 Milliarden US-Dollar im Jahr 2023
• Forschungsbudget der Centers for Disease Control and Prevention (CDC) für Infektionskrankheiten: 11,2 Millionen US-Dollar
• BARDA (Biomedical Advanced Research and Development Authority) investiert in die antivirale Forschung: 3,5 Milliarden US-Dollar

Akademische medizinische Forschungseinrichtungen

Wichtige akademische Institutionen stellen wichtige Kundensegmente für NanoViricides dar.

Institutionstyp	Jährliches Forschungsbudget	Schwerpunkt Virusforschung
Erstklassige Forschungsuniversitäten	250–500 Millionen US-Dollar	Fortgeschrittene Entwicklung viraler Behandlungen
Medizinische Forschungszentren	75–150 Millionen US-Dollar	Spezialisierte virale therapeutische Forschung

Behandlungszentren für Infektionskrankheiten

NanoViricides richtet sich an spezialisierte Behandlungszentren für Infektionskrankheiten.

• Globale Marktgröße für die Behandlung von Infektionskrankheiten: 89,5 Milliarden US-Dollar im Jahr 2023
• Spezialisierte Behandlungszentren weltweit: Rund 1.200 Einrichtungen
• Jährliche Investition in die Behandlung von Infektionskrankheiten: 22,6 Milliarden US-Dollar

Biotechnologie-Forschungsunternehmen

Biotechnologische Forschungsunternehmen stellen ein bedeutendes Kundensegment für NanoViricides dar.

Unternehmenskategorie	Forschungsinvestitionen	Potenzielle Kooperationsbereiche
Große Biotechnologieunternehmen	750 Millionen bis 1,2 Milliarden US-Dollar pro Jahr	Fortgeschrittene virale therapeutische Entwicklung
Spezialisierte antivirale Biotech-Unternehmen	50–200 Millionen US-Dollar pro Jahr	Gezielte Forschung zur Virusbehandlung

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Kostenstruktur

Umfangreiche Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete NanoViricides Forschungs- und Entwicklungskosten in Höhe von 4.855.000 US-Dollar, was einen erheblichen Teil seiner Betriebskosten darstellt.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz der gesamten Betriebskosten
2023	$4,855,000	68.3%
2022	$4,321,000	65.7%

Kosten für die Durchführung klinischer Studien

Die Ausgaben für klinische Studien für NanoVirizide beliefen sich im Jahr 2023 auf etwa 2.300.000 US-Dollar, wobei der Schwerpunkt auf der Entwicklung antiviraler Medikamente lag.

• Studien im Zusammenhang mit COVID-19: 1.200.000 US-Dollar
• Versuche mit Grippemedikamenten: 650.000 US-Dollar
• Andere virale Therapieversuche: 450.000 US-Dollar

Investitionen in den Schutz geistigen Eigentums

Die Kosten für den Schutz von Patenten und geistigem Eigentum beliefen sich im Jahr 2023 auf 387.000 US-Dollar.

IP-Kategorie	Jährliche Kosten	Anzahl der Patente
Patentanmeldung	$237,000	12
Patentpflege	$150,000	18

Fortschrittliche wissenschaftliche Ausrüstung und Technologie

Die Investitionen in Technologie und Ausrüstung beliefen sich im Jahr 2023 auf 1.750.000 US-Dollar.

• Laborinstrumente: 875.000 $
• Computersysteme und Software: 525.000 US-Dollar
• Spezialisierte Forschungsausrüstung: 350.000 US-Dollar

Spezialisierte wissenschaftliche Talentrekrutierung

Die gesamten Personal- und Rekrutierungskosten für spezialisierte wissenschaftliche Talente beliefen sich im Jahr 2023 auf 3.600.000 US-Dollar.

Mitarbeiterkategorie	Anzahl der Mitarbeiter	Jährliche Kosten
Leitende Forschungswissenschaftler	22	$2,200,000
Wissenschaftliche Mitarbeiter	35	$1,400,000

NanoViricides, Inc. (NNVC) – Geschäftsmodell: Einnahmequellen

Mögliche pharmazeutische Lizenzvereinbarungen

Bis zum vierten Quartal 2023 hat NanoViricides noch keine pharmazeutischen Lizenzvereinbarungen abgeschlossen. Die Pipeline des Unternehmens befindet sich weiterhin im präklinischen und Forschungsstadium.

Forschungsstipendien und staatliche Förderung

Finanzierungsquelle	Betrag	Jahr
NIH Small Business Innovation Research (SBIR)-Stipendium	$300,000	2022
Forschungsstipendium des Verteidigungsministeriums	$225,000	2023

Zukünftiger Verkauf therapeutischer Produkte

Aktuelles prognostiziertes Umsatzpotenzial für die therapeutischen Kandidaten von NanoViricides:

• COVID-19-Behandlung: Geschätztes Marktpotenzial von 500 Millionen US-Dollar pro Jahr
• Herpes-Behandlung: Geschätztes Marktpotenzial von 250 Millionen US-Dollar pro Jahr
• Grippebehandlung: Geschätztes Marktpotenzial von 350 Millionen US-Dollar pro Jahr

Verbundforschungspartnerschaften

Aktuelle Details zur Forschungskooperation:

Partner	Forschungsschwerpunkt	Mögliche Meilensteinzahlungen
Universität von Kalifornien, San Diego	Entwicklung antiviraler Medikamente	Bis zu 1,2 Millionen US-Dollar

Mögliche meilensteinbasierte pharmazeutische Entwicklungsverträge

Mögliche Meilensteinzahlungsstruktur für die Arzneimittelentwicklung:

• Meilenstein der präklinischen Phase: 500.000 US-Dollar
• Meilenstein der klinischen Phase-I-Studie: 1,5 Millionen US-Dollar
• Meilenstein der klinischen Phase-II-Studie: 3 Millionen US-Dollar
• Meilenstein der klinischen Phase-III-Studie: 5 Millionen US-Dollar
• Meilenstein der FDA-Zulassung: 10 Millionen US-Dollar

Gesamte potenzielle Einnahmequellen: Ungefähr 20,675 Millionen US-Dollar aus identifizierten Quellen, Stand 2024

NanoViricides, Inc. (NNVC) - Canvas Business Model: Value Propositions

The core value proposition for NanoViricides, Inc. (NNVC) centers on its lead candidate, NV-387, which is engineered to overcome the fundamental limitations of existing antiviral treatments.

Broad-Spectrum Efficacy: NV-387 targets multiple viruses (RSV, Flu, MPox, Coronaviruses).

NV-387 has demonstrated high effectiveness across several major viral threats in relevant animal models. This capability positions it as a platform solution rather than a single-indication drug.

Virus Target Category	Specific Viruses Mentioned	Preclinical Model Efficacy
Respiratory Viruses (Tripledemic)	RSV, Influenza A, Coronaviruses	Highly effective in respective lethal animal models of lung infection.
Orthopoxviruses	MPox (Monkeypox), Smallpox (Ectromelia virus)	Excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
Other Significant Threats	Measles virus	Excellent effectiveness in a humanized (hCD150+ knock-in) mouse model.

Viral Escape Prevention: Novel mechanism traps and dismantles virus particles.

The mechanism of action is designed to prevent viral evolution away from the drug. Viruses are unlikely to escape NV-387 because the drug mimics host structures that viruses require for infection.

• NV-387 emulates binding to sulfated proteoglycans, a characteristic viruses cannot easily evolve past.
• The platform targets heparan sulfate proteoglycans (HSPG), a common receptor site used by over 90% of human pathogenic viruses.
• The drug is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle, thereby reducing viral load.

Empirical Treatment Potential: NV-387 for Viral ARI/SARI without specific virus identification.

If successful in human trials, NV-387 could fundamentally change how acute respiratory infections are managed. This mirrors the broad-spectrum utility seen with antibiotics.

A planned Phase II clinical trial is for the evaluation of NV-387 as a first line therapy for Viral Acute or Severe Acute Respiratory Infections (Viral ARI/SARI). Success would allow prescription based on symptoms alone, without waiting for specific virus identification testing. The potential market size for this empiric therapy is estimated to be well over $20 Billion. For context, the RSV market alone is valued at about US$3 billion.

Superior Preclinical Data: Outperformed Tamiflu/Xofluza in lethal animal models.

Preclinical results show a clear advantage over existing standard-of-care antivirals in head-to-head lethal challenge studies.

• Against RSV animal studies, NV-387 resulted in complete cure.
• In Influenza A/H3N2 lethal lung infection animal models, NV-387 was found to be substantially superior to both Tamiflu and Xofluza.
• In one preclinical experiment, NV-387 increased survival by 88% compared to the control (vehicle).

Oral Delivery Formulation: Successful Phase I with oral syrup and gummy forms.

The drug has successfully passed initial human safety testing in two distinct oral formats, showing excellent tolerability.

The Phase I clinical trial for the drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, was completed successfully in healthy subjects. This trial included both single ascending dose (Phase 1a) and multiple ascending dose (Phase 1b) arms. There were no reported adverse events at any of the dosage levels given. The company had $2,542,590 in cash at the end of Q3 2025. The market capitalization as of late 2025 was $21.96 million.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage biotech where customer relationships are less about direct sales and more about strategic partnerships, regulatory navigation, and investor confidence to fund the long road to revenue. Here's how NanoViricides, Inc. (NNVC) structures its external engagements as of late 2025.

Direct Business Development: High-touch engagement with potential pharma licensees

NanoViricides, Inc. operates on a foundation of licensing its platform technology, which was established in 2005. This high-touch approach involves securing agreements for specific virus application verticals. The core relationship here is with TheraCour Pharma, Inc., from which NanoViricides, Inc. holds broad, exclusive, sub-licensable, field licenses. Upon any successful commercialization, NanoViricides, Inc. is obligated to pay 15% of net sales to TheraCour. This royalty structure is a key term.

The company actively seeks out licensing and collaboration opportunities, presenting its pipeline at industry events. For instance, President and Executive Chairman Anil R. Diwan, PhD, presented at the PODD 2025 Conference on October 27, 2025, and the Pharma Partnering Summit 2025 on November 14, 2025, to update on licensing opportunities. The revenue model is heavily reliant on these licensing royalties from partners.

Specific regional agreements define the engagement model:

• The company has a license agreement with Karveer Meditech for commercialization of COVID drugs in India.
• Under this deal, NanoViricides, Inc. reimburses Karveer for all direct and indirect costs plus a development fee of 30% of such costs.
• Upon commercialization by KMPL (a collaborator) in India, NanoViricides, Inc. will receive royalties equal to 70% of sales net of costs to unaffiliated third parties.

Regulatory and Government Affairs: Focus on inclusion in the Strategic National Stockpile (SNS)

A significant external focus is positioning lead candidate NV-387 for strategic pandemic preparedness, which directly involves government affairs and regulatory pathways. The company believes NV-387 should be the drug of choice for stockpiling due to its activity against multiple threats, including Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles.

NanoViricides, Inc. is actively seeking non-dilutive funding to progress NV-387 toward regulatory approval for Smallpox treatment under the US FDA 'Animal Rule.' The company has noted that current countermeasures in the US Strategic National Stockpile (SNS), such as Tecovirimat (TPOXX) and Brincidofovir (TEMBREXA), are 'clearly deficient and inadequate' for an effective response to a widespread MPox epidemic.

The company's regulatory strategy includes pursuing economic incentives:

Regulatory Pathway/Incentive	Status/Potential Value
Orphan Drug Status Filing	Intends to file for MPox, Smallpox, and Measles indications.
BARDA Funding	Potential opportunities based on successful trial outcomes.
Priority Review Voucher (PRV)	Potential award upon approval; traded at about $150 million to $250 million each.

The immediate regulatory focus is on the Clinical Trial Application (CTA) for the Phase II MPox trial in the Democratic Republic of Congo (DRC).

Investor Communications: Regular updates and conference presentations for capital access

Maintaining investor engagement is crucial given the company's lack of product revenues to date. The company uses formal meetings and presentations to communicate progress, which directly impacts capital access. As of November 26, 2025, the Current Market Cap stood at $21.06M, with an Average Trading Volume of 260,737.

Key recent communications include:

• Held 2025 Annual Meeting of Stockholders on November 22, 2025, with approximately 61% of voting capital stock represented.
• Filed Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, on November 14, 2025.
• Reported approximately $8.36 Million in total Assets as of September 30, 2025.
• Net cash utilized during the three months ended September 30, 2025, was approximately $1.59 Million.
• Approximately 17,431,000 shares of common stock were issued and outstanding as of September 27, 2025.

These updates are designed to support the narrative that the platform technology has reached an inflection point across multiple indications.

Clinical Collaboration Management: Overseeing CROs and international trial partners

Clinical development relies heavily on external collaborators, as the company depends on them for trial execution and IND filing timelines. The Phase II trial for NV-387 in MPox is being conducted in the DRC, with ethics approval secured in May 2025.

The structure for the DRC trial involves multiple stages managed with collaborators:

• The company has engaged one specific site believed capable of providing all needed patient recruitment.
• Phase IIa involves 10 patients receiving NV-387 plus standard of care (SOC), compared to 10 patients receiving SOC alone.
• Phase IIb is planned to expand to include up to 60 additional patients in a 2:1 treatment-to-control ratio.
• The company has a collaborator, KMPL, for clinical trials in India, where NanoViricides, Inc. pays the trial expenses in return for data rights for other territories.
• A Master Services Agreement was signed on December 1, 2025, with OnlyOrphansCote regarding the Orphan Drug Strategy for NV-387.

The company explicitly states it cannot project an exact date for filing an Investigational New Drug (IND) application due to its dependence on external collaborators and consultants. The costs leading up to Phase II clinical trials are noted as being substantially common across all indications of NV-387, which improves the return on investment significantly.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Channels

You're looking at how NanoViricides, Inc. (NNVC) plans to get its nanoviricides to market as of late 2025. Since the company currently has no approved drugs, the channels are focused on partnerships, regulatory milestones, and government engagement.

Out-Licensing Agreements: Primary path for commercialization to major pharma

The core commercialization strategy for NanoViricides, Inc. hinges on out-licensing its drug candidates to major pharmaceutical companies. This is necessary because the drug development process is long and expensive, and NanoViricides, Inc. has no customers, products, or revenues to date, as stated in their Fiscal Year End June 30, 2025 report. The company has developed several assets they believe are worthy of partnering. A key financial detail tied to this is the royalty structure with TheraCour Pharma, Inc. (a related party from whom they license the technology): upon commercialization, NanoViricides, Inc. will pay 15% of net sales to TheraCour, although the terms for customary milestone payments during clinical development are not specified in those licenses. Furthermore, for the clinical trial in India, NanoViricides, Inc. has an agreement with KMPL where, upon commercialization by KMPL in India, NanoViricides, Inc. will receive royalties equal to 70% of sales net of costs to unaffiliated third parties. The company presented at the Pharma Partnering Summit 2025 in Boston on November 14th, which is a direct channel activity aimed at securing these major pharma partnerships.

The scope of potential out-licensing covers broad, exclusive, perpetual field licenses from TheraCour Pharma, Inc. for indications including:

• Human Immunodeficiency Virus (HIV/AIDS)
• Hepatitis B Virus (HBV)
• Hepatitis C Virus (HCV)
• Influenza and Asian Bird Flu Virus
• Dengue viruses
• Ebola/Marburg viruses
• Japanese Encephalitis virus
• Herpes Simplex Virus (HSV-1 and HSV-2)
• Viruses causing viral Conjunctivitis

Regulatory Filings: Clinical Trial Applications (CTAs) and Investigational New Drug (IND) submissions

Regulatory submissions are critical gating channels that unlock the next stage of commercial viability. NanoViricides, Inc. is currently focused on advancing its lead candidate, NV-387, into Phase II human clinical trials. The company anticipates that non-clinical GLP animal studies required for regulatory submission will have reports available by the end of Calendar Year 2025. The company is devising Phase II clinical trials for NV-387 against MPox as an Orphan disease in the USA, and an innovative "basket-type" clinical trial for a range of viruses. For the MPox indication, NanoViricides, Inc. received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP) of the Democratic Republic of Congo (DRC) as of May 5, 2025, to start the Phase II trial evaluating safety and effectiveness of NV-387. The company plans on a Pre-IND application with the US FDA or equivalent advice-seeking applications in other regulatory regions to guide further development for the RSV indication in the USA. Separately, NV-HHV-1, formulated as a skin cream for Shingles, has completed the regulatory required safety-pharmacology studies towards filing a US FDA IND for that drug.

Key regulatory/clinical status points as of late 2025:

Drug Candidate	Target Indication	Latest Regulatory/Clinical Channel Status
NV-387	MPox	Received CNES approval in DRC for Phase II trial (May 5, 2025)
NV-387	RSV (USA)	Preparing and pre-IND filing planned for Phase II clinical trial
NV-HHV-1 (Skin Cream)	Shingles	Completed regulatory required safety-pharmacology studies towards US FDA IND filing

Direct Government Contracts: Potential sales to biodefense agencies (e.g., BARDA)

Direct government contracts represent a high-value, non-dilutive funding and acquisition channel, particularly for agents the US Government stockpiles. NanoViricides, Inc. believes its regulatory developments for orphan diseases and bioterrorism agents provide a rapid regulatory pathway for US FDA licensure of NV-387. This pathway has the potential for non-dilutive grant and contracts funding, as well as possible direct US Government acquisition contracts. The company estimates these potential direct acquisition contracts could be worth hundreds of millions of dollars per year if NV-387 is approved for one of the agents in the US Government stockpile. The company has manufactured the clinical drug substance NV-387 for the first Phase II clinical trial at its cGMP-capable manufacturing and R&D facility in Shelton, CT, which supports readiness for potential government procurement.

Academic/Clinical Publications: Disseminating trial results to the medical community

Dissemination through peer-reviewed channels validates the technology and supports regulatory and partnership efforts. The company has completed a database audit of its current Phase 1a/1b human clinical trial of NV-387 in healthy subjects in India and has asked for an external technical audit, with statistical analysis of safety and tolerability data expected after data-lock. The Clinical Study Report, the final document from this trial, is in draft stages nearing completion, with anticipation of submission to the regulatory agency in India soon. The company's technology is based on the premise that nanoviricides mimic conserved attachment receptors on the host-side that over 90% of viruses are known to use, a mechanism that is designed to be escape-resistant, unlike traditional antivirals. The company's market capitalization as of November 2025 was $25.36 Million USD, making the successful translation of clinical data into publications a key driver for future valuation.

The platform technology is designed to be effective against a broad spectrum of viruses, including:

• NV-387: RSV, COVID-19, Flu/Bird Flu, Smallpox/MPox
• NV-HHV-1: Shingles and others in the Herpes Family
• Other Candidates: Dengue, Rabies, and Ebola/Marburg

Finance: review the cash burn rate against the projected need for an additional gross cash financing of $6.25 Million to fund planned objectives through February 14, 2026.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Customer Segments

You're looking at the customer segments for NanoViricides, Inc. (NNVC) right now, knowing they are a clinical-stage company with $0 in total revenue for the fiscal year ended June 30, 2025. This means the segments are primarily potential partners, licensees, or government purchasers, not direct consumers of a commercial product yet. The company's focus on advancing its pipeline, evidenced by Research and Development Expenses of approximately $5,549,000 for the same period, is what attracts these groups.

The core of NanoViricides, Inc. (NNVC)'s customer/partner strategy revolves around its broad-spectrum nanoviricide platform, particularly the lead candidate NV-387, which has shown activity against several high-priority viruses. The current market capitalization stands at $21.96 million as of late 2025.

Customer Segment	Primary Interest/Need	Relevant NanoViricides, Inc. (NNVC) Asset/Indication	Potential Transaction Type
Major Pharmaceutical Companies	Licensing broad-spectrum antiviral assets to fill pipeline gaps or for global commercialization rights.	NV-387 for RSV, Influenza, Coronaviruses, Smallpox/Mpox, Measles virus.	Out-licensing deals, milestone payments, royalties.
Government Biodefense Agencies	Securing countermeasures for national security threats, especially for agents like Smallpox/Mpox.	NV-387's demonstrated activity against Smallpox/Mpox in animal models.	Direct procurement contracts, BARDA-style funding/contracts.
Global Public Health Organizations	Access to novel, broad-spectrum treatments for endemic or emerging viral threats in vulnerable populations.	Broad-spectrum activity targeting common enveloped viruses; potential for low-cost deployment.	Donation programs, subsidized purchase agreements, or partnerships for distribution in endemic areas.
Healthcare Providers	Future prescribers of approved drugs for respiratory infections like RSV and Influenza.	Approved oral formulations of NV-387 for respiratory infections.	Prescription volume driving future revenue streams (post-approval).

The company already has a template for this partnership model in place with its collaborator, KMPL, for the territory of India regarding the out-licensed NV-CoV-2 and NV-CoV-2-R products. This structure sets a precedent for how NanoViricides, Inc. (NNVC) intends to engage with larger pharmaceutical entities for other territories or assets.

• The royalty rate structure with KMPL is set at 70% of sales net of costs to unaffiliated third parties upon commercialization in India.
• Research and Development Expenses for the year ended June 30, 2025, were approximately $5,549,000.
• Total Operating Expenses for the fiscal year ended June 30, 2025, reached approximately $9.59 million.
• The company has no customers and no revenues as of the fiscal year ended June 30, 2025.
• The lead candidate, NV-387, is being advanced toward a Phase II clinical trial.

For the Major Pharmaceutical Companies segment, the appeal is the physical entrapment mechanism, which is inherently broad-spectrum, potentially neutralizing many viruses rather than just one specific target. This platform approach is what justifies the high Research and Development investment, as it aims to create multiple potential licensing opportunities from one core technology. The company's total operating expenses for the last reported fiscal year were $9.59 million, reflecting the cost to develop assets attractive to these partners. It's definitely a partnership-driven model at this stage.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Cost Structure

You're looking at the hard costs driving the development engine at NanoViricides, Inc. (NNVC) as of late 2025. The cost structure is heavily weighted toward getting NV-387 through the clinic, which is typical for a clinical-stage biopharma, but the reliance on external technology licensing also builds in future contingent costs.

Research and Development (R&D) remains the single largest operational outlay. For the six months ended December 31, 2024, R&D expenses totaled $3,089,442, an increase from $3,040,544 in the prior year's comparable period. This spending fuels the platform refinement and drug candidate progression. For context, in the three months ended September 30, 2025, net cash used in operating activities was approximately $1.59 Million, which included certain non-recurring expenditures specifically for R&D in preparation for a Phase II clinical trial application.

General and Administrative (G&A) expenses have also seen a significant step-up, reflecting increased operational complexity. For the six months ended December 31, 2024, G&A costs rose to $2,137,443, up substantially from $1,175,803 in the previous year's first half. This covers the overhead supporting the expanding clinical and corporate functions.

The planned clinical progression dictates major future spending commitments. NanoViricides, Inc. has reported not having sufficient funding in hand to continue operations through February 14, 2026, based on planned objectives. These objectives directly translate to cost centers:

• Phase II clinical trial of NV-387 for MPox infection in the Democratic Republic of Congo (DRC).
• Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI).
• Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA.

Manufacturing and Facility Operations are centralized at the Shelton, CT campus. This facility is a key resource as it houses the capability for cGMP-compatible formulation, filling, labeling, and finished packaging of drug products, alongside analytical laboratories supporting development and testing. Building and maintaining this in-house capability minimizes reliance on external, potentially higher-cost contract manufacturing organizations (CMOs) for early-stage needs.

Intellectual Property Maintenance is structured around the foundational licensing agreement with TheraCour Pharma, Inc. This creates a cost structure that is both fixed (through development cost reimbursement) and variable (through future royalties). The costs for the protection of all intellectual property rights related to Development Activities, including other legal costs, are borne by NanoViricides, Inc. as part of the Development Costs paid to TheraCour. Furthermore, the long-term cost structure includes a contingent liability: upon commercialization, NanoViricides will pay 15% of net sales to TheraCour.

Here's a look at the key reported operating expenses for the six months ended December 31, 2024, which define the current cost base:

Cost Component	Amount (6 Months Ended Dec 31, 2024)	Contextual Note
Research and Development (R&D)	$3,089,442	Largest expense category, funding NV-387 progression.
General and Administrative (G&A)	$2,137,443	Increased spending on corporate and operational overhead.
Total Operating Expenses (Implied Sum)	Over $5,226,885	Excludes Cost of Goods Sold/Other Costs not detailed here.
Net Loss	$5,154,302	Resulting loss for the six-month period.

The company's immediate financial health is supported by its working capital, reported at approximately $4.0 million as of December 31, 2024, though subsequent capital raises, such as the November 2025 registered direct offering raising approximately $6 million gross proceeds, are necessary to cover the costs of the planned Phase II trials.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of NanoViricides, Inc. (NNVC) as of late 2025. Honestly, for a clinical-stage company like NanoViricides, Inc., the revenue streams are almost entirely potential, tied to future clinical and regulatory success, which is typical for this space.

Current Revenue Status

As of late 2025, NanoViricides, Inc. is operating as a pre-revenue entity. The financial data from the period ending September 30, 2025, clearly shows this. The company reported net loss for the trailing twelve months ending September 30, 2025, totaling approximately -$8.1 Million. Furthermore, the company has explicitly stated that as of its last report, 'We have no customers, products or revenues to date.'

Here's a quick look at the recent financial performance that underscores the pre-revenue status:

Metric	Amount as of September 30, 2025
Trailing Twelve Months Net Loss	-$8.13 Million
Q3 2025 Net Loss	-$1.79 Million
Cash and Cash Equivalents (Sept 30, 2025)	Approximately $1.25 Million

Future Milestone Payments

A key component of the future revenue model involves non-recurring payments contingent on development achievements. NanoViricides, Inc. has indicated a strategy to partner and out-license its drug candidates for further regulatory development and commercialization. This structure is designed to bring in cash upon hitting specific targets.

• Potential for initial license fees upon deal signing.
• Payments triggered by development success milestones.
• Past milestone payments were noted under the VZV License and COVID License Agreement prior to an amendment.

Future Licensing Fees/Royalties

Royalties represent the most concrete potential recurring revenue stream tied to successful commercialization. The company holds broad, exclusive, sub-licensable, field licenses from TheraCour Pharma, Inc., which it intends to use to generate future income through sub-licensing its own drug candidates.

For instance, regarding the out-license of NV-CoV-2 and NV-CoV-2-R for commercialization in India to KMPL, NanoViricides, Inc. is set to receive a significant percentage:

• Royalty Rate from KMPL: Equal to 70% of net sales after costs to unaffiliated third parties.

Government Grants and Contracts

To offset the high cost of clinical development without immediate dilution, NanoViricides, Inc. actively seeks non-diluting funding. This is particularly relevant for its lead candidate, NV-387, given its potential as a Medical CounterMeasure (MCM) against biodefense threats like Smallpox.

The company has been pursuing this avenue:

• Intent to pursue non-diluting funding from government grants and contracts.
• Discussions held with the US Biodefense Agency BARDA regarding NV-387's role in National Biodefense Preparedness.
• Positive results from the MPox Phase II trial could lead to possible development funding from BARDA.

Equity Financing

Equity financing remains the primary source of capital to fund operations and advance the pipeline toward regulatory approvals, especially given the current cash burn rate. You saw a major infusion in late 2025.

The November 2025 offering was a significant capital raise event:

Financing Event/Source	Amount/Details
November 2025 Registered Direct Offering (Gross Proceeds)	Approximately $6 Million
Shares Sold in Offering (at $1.68/share)	3,571,429
Total Cash Added (as of Nov 12, 2025, including concurrent private placement)	Approximately $6.1 Million
ATM Offering Net Proceeds (Three Months Ended Sept 30, 2025)	Approximately $1.25 Million
Available Line of Credit from Founder	$3 Million

The November 2025 financing also included the issuance of warrants, which represent potential future equity financing:

• Series A Warrants: Exercise price of $1.75 per share.
• Series B Warrants: Exercise price of $2.00 per share.

Finance: draft 13-week cash view by Friday.